Spirea Limited, a Cambridge company created to advance a new generation of antibody-drug conjugate (ADC) therapeutics, has secured funding of £2.4 million in an investment round led by Jonathan Milner and Cambridge Enterprise.
US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels also participated in the round.
Spirea, a spin-out from the University of Cambridge, has previously received investment from IP Group, Cambridge Enterprise, Start Codon, Jonathan Milner, o2h Ventures and Syndicate Room, and is supported by a number of successful, high-profile board members from the life sciences.
